Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
| Index | Nasdaq Biotechnology |
| Investment focus | Equity, United States, Health Care |
| Fund size | EUR 43 m |
| Total expense ratio | 0.35% p.a. |
| Replication | Physical (Optimized sampling) |
| Legal structure | ETF |
| Strategy risk | Long-only |
| Sustainability | No |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in EUR) | 22.84% |
| Inception/ Listing Date | 5 March 2018 |
| Distribution policy | Distributing |
| Distribution frequency | Semi annually |
| Fund domicile | Ireland |
| Fund Provider | iShares |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | State Street Fund Services (Ireland) Limited |
| Investment Advisor | |
| Custodian Bank | State Street Custodial Services (Ireland) Limited |
| Revision Company | Deloitte |
| Fiscal Year End | 31 May |
| Swiss representative | BlackRock Asset Management Schweiz AG |
| Swiss paying agent | State Street Bank International GmbH, Munich, Zurich Branch |
| Germany | 30% tax rebate |
| Switzerland | ESTV Reporting |
| Austria | Tax Reporting Fund |
| UK | UK Reporting |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
| Securities lending | Yes |
| Securities lending counterparty | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
| Vertex Pharmaceuticals | 7.66% |
| Gilead Sciences, Inc. | 7.47% |
| Amgen, Inc. | 7.24% |
| Regeneron Pharmaceuticals, Inc. | 5.82% |
| Alnylam Pharmaceuticals | 5.04% |
| AstraZeneca PLC ADR | 3.67% |
| Insmed | 3.54% |
| argenx | 2.16% |
| Biogen, Inc. | 1.89% |
| United Therapeutics | 1.77% |
| United States | 77.24% |
| Ireland | 1.20% |
| Bermuda | 1.15% |
| Germany | 1.01% |
| Other | 19.40% |
| Health Care | 83.24% |
| Other | 16.76% |
| Broker | Rating | Execution fee | Account fee | |
|---|---|---|---|---|
| 0.00€ | 0.00€ | View offer* | |
| 0.00€ | 0.00€ | View offer* | |
| 0.00€ | 0.00€ | View offer* |
| YTD | +17.32% |
| 1 month | +1.59% |
| 3 months | +19.32% |
| 6 months | +30.37% |
| 1 year | +13.91% |
| 3 years | +21.33% |
| 5 years | +27.23% |
| Since inception (MAX) | +74.47% |
| 2024 | +5.34% |
| 2023 | +0.76% |
| 2022 | -5.13% |
| 2021 | +8.09% |
| Current dividend yield | 0.25% |
| Dividends (last 12 months) | EUR 0.02 |
| Period | Dividend in EUR | Dividend yield in % |
|---|---|---|
| 1 Year | EUR 0.02 | 0.28% |
| 2024 | EUR 0.03 | 0.47% |
| 2023 | EUR 0.02 | 0.40% |
| 2022 | EUR 0.03 | 0.42% |
| 2021 | EUR 0.01 | 0.26% |
| Volatility 1 year | 22.84% |
| Volatility 3 years | 20.11% |
| Volatility 5 years | 22.77% |
| Return per risk 1 year | 0.61 |
| Return per risk 3 years | 0.33 |
| Return per risk 5 years | 0.22 |
| Maximum drawdown 1 year | -23.65% |
| Maximum drawdown 3 years | -25.58% |
| Maximum drawdown 5 years | -31.04% |
| Maximum drawdown since inception | -31.04% |
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | OM3E | - - | - - | - |
| London Stock Exchange | USD | BTEE | BTEE LN INAVBTDU | BTTE.L |
| Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
|---|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF | 743 | 0.35% p.a. | Accumulating | Sampling |
| Invesco Nasdaq Biotech UCITS ETF | 375 | 0.40% p.a. | Accumulating | Swap-based |